Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Ligand Pharmaceuticals announced a proposed private placement of $550 million in convertible senior notes due 2031. The company plans to use portions of the proceeds to repurchase shares and fund convertible note hedging transactions to offset potential dilution. Remaining proceeds will support general corporate purposes, including investments and …